Post Profile






Significant survival gains from neoadjuvant chemotherapy for high-risk soft tissue sarcoma

(European Society for Medical Oncology) Neoadjuvant chemotherapy with an anthracycline plus ifosfamide was associated with significant survival gains in patients with soft tissue sarcoma of the trunk or extremities who are at high-risk of recurrence, in an interim analysis that led to the early discontinuation of a trial presented today at the ESMO 2016 Congress in Copenhagen.
read more

share

Related Posts


Votrient (Pazopanib) For Soft Tissue Sarcoma Approved By FDA

Health : Medical News Today

Votrient (pazopanib) has been approved by the FDA for the treatment of soft tissue sarcoma in patients who have already received chemotherapy. Soft tissue sarcoma is a type of cancer that starts in the fibrous tissue blood vessels, ...

Ipilimumab as adjuvant therapy improves overall survival in high risk stage III melanoma

Health : EurekAlert: Health

(European Society for Medical Oncology) Ipilimumab as adjuvant therapy significantly improves overall survival in patients with high risk stage III melanoma, according to the EORTC 18071 phase III trial results presented for the fir...

Votrient (Pazopanib) Gets FDA Panel Green Light For Advanced Soft Tissue Sarcoma Treatment

Health : Medical News Today

The FDA's Oncologic Drugs Advisory Committee (ODAC) has recommended the approval of Votrient (pazopanib) for the treatment of the rare cancer advanced soft tissue sarcoma. Patients who were already administered chemotherapy will be ...

Prediction Of Increased Survival In Sarcoma Patients Using Early PET Response To Neoadjuvant Chemo

Health : Medical News Today

An early Positron Emission Tomography (PET) response after the initial cycle of neoadjuvant chemotherapy can be used to predict increased survival in patients with soft tissue sarcomas, according to a study by researchers with UCLA'...

Early PET Response to Neoadjuvant Chemo Predicts Increased Survival in Sarcoma Patients

Health : Newswise Medical News

An early Positron Emission Tomography (PET) response after the initial cycle of neoadjuvant chemotherapy can be used to predict increased survival in patients with soft tissue sarcomas, according to a study by researchers with UCLA'...

Comments


Copyright © 2016 Regator, LLC